Cite
HARVARD Citation
Degryse, S. et al. (2018). Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 32 (12), p. 2731. [Online].